Last reviewed · How we verify

Crizotinib Capsules — Competitive Intelligence Brief

Crizotinib Capsules (Crizotinib Capsules) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ALK/ROS1 tyrosine kinase inhibitor. Area: Oncology.

phase 3 ALK/ROS1 tyrosine kinase inhibitor ALK, ROS1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Crizotinib Capsules (Crizotinib Capsules) — Shouyao Holdings (Beijing) Co. LTD. Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Crizotinib Capsules TARGET Crizotinib Capsules Shouyao Holdings (Beijing) Co. LTD phase 3 ALK/ROS1 tyrosine kinase inhibitor ALK, ROS1
X-396 (ensartinib) X-396 (ensartinib) Xcovery Holdings, Inc. phase 3 ALK and ROS1 kinase inhibitor ALK, ROS1
PF-02341066 PF-02341066 Pfizer phase 3 ALK/ROS1 tyrosine kinase inhibitor ALK, ROS1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ALK/ROS1 tyrosine kinase inhibitor class)

  1. Pfizer · 1 drug in this class
  2. Shouyao Holdings (Beijing) Co. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Crizotinib Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/crizotinib-capsules. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: